Table of Contents
What HHS Announced
On June 30, 2026, the Department of Health and Human Services (HHS) announced that it will terminate emergency use authorization (EUA) declarations for certain COVID-19 drugs and medical devices. The agency stated clearly that the circumstances justifying these authorizations no longer exist.
This decision marks a major policy milestone. HHS originally issued the EUA declarations in 2020 to accelerate access to medical products during the early, uncertain months of the COVID-19 pandemic. Now, more than six years later, the regulatory landscape has shifted significantly. As a result, HHS is formally winding down the emergency authorization framework that shaped pandemic-era healthcare.
Key EUA Expiration Dates
HHS set separate deadlines for different product categories. Healthcare organizations must act according to each specific timeline.
Drugs and Biological Products
The EUA declaration for drugs and biological products will end on June 29, 2027. This gives manufacturers, providers, and health systems approximately one year to transition affected products to full FDA approval — or to discontinue their use entirely.
Medical Devices
The EUA declaration for medical devices will expire earlier — on December 26, 2026. Hospitals and clinical teams must therefore move faster to assess which devices still operate under emergency authorization status. Any delay in this review increases compliance risk.
Why HHS Is Ending These Authorizations
HHS based its decision on a clear regulatory rationale: the emergency conditions that once justified EUA status no longer apply. The federal COVID-19 public health emergency ended in May 2023. Since then, the healthcare system has adapted in significant ways.
First, hospitals gained broader access to fully FDA-approved COVID-19 treatments. Second, clinical evidence has grown substantially, allowing the FDA to conduct standard regulatory reviews for many COVID-19 products. Third, vaccination and treatment infrastructure has stabilized across the country.
Consequently, HHS determined that continuing the emergency framework beyond its necessity was unjustified. Moreover, this move aligns with broader federal efforts to normalize post-pandemic healthcare regulation. Rather than maintaining an indefinite emergency posture, policymakers are returning COVID-19 products to the standard FDA regulatory pathway.
ongoing debate over HHS funding priorities
What Products Are Affected
The EUA declarations cover a range of drugs, biological products, and medical devices authorized specifically for COVID-19 treatment. However, not all COVID-19 products fall under EUA status. Many have already received full FDA approval during or after the pandemic period.
Affected products typically include:
- Therapeutics authorized under EUA but not yet fully FDA-approved
- Diagnostic and treatment devices covered under the COVID-19 EUA declarations
- Biological products still operating under emergency authorization
Providers should verify the regulatory status of each product with the manufacturer or the FDA directly. Assumptions about approval status can create serious compliance and liability issues.
What This Means for Hospitals and Providers
This regulatory change carries direct implications for hospitals, health systems, and clinical teams across the country.
First, providers must audit current COVID-19 treatment protocols to identify any products that rely solely on EUA status. Second, supply chain and pharmacy teams should confirm whether affected drugs or devices are pursuing or have already received full FDA approval.
Furthermore, hospitals need to communicate these changes to clinical staff in a timely manner. Clinicians who prescribe or use EUA-authorized products must clearly understand the new transition timelines. Delays in internal communication could create care gaps or regulatory compliance failures.
Additionally, procurement teams should begin evaluating FDA-approved alternatives for any treatments or devices that may lose authorization status before achieving full approval. Proactive sourcing protects both patient safety and hospital operations.
Next Steps for Healthcare Organizations
Healthcare leaders should take several concrete actions now — before either EUA deadline arrives.
Review your inventory. Start by identifying all COVID-19 drugs and devices currently in use at your facility. Flag any product whose regulatory status is unclear.
Consult the FDA’s EUA product list. The FDA maintains an updated list of products authorized under emergency declarations. Cross-reference this list against your current formulary and device inventory.
Engage compliance and legal teams early. Both EUA termination declarations were published in the Federal Register on June 30, 2026. Compliance officers should review the full regulatory text to assess any specific obligations or transition requirements.
Monitor for further guidance. HHS and the FDA may issue additional guidance as the expiration dates approach. Subscribe to Federal Register alerts and AHA advisory updates to stay informed.
Act faster on devices than on drugs. The medical device deadline (December 26, 2026) is nearly six months sooner than the drug deadline. Therefore, device-related reviews and procurement decisions require the most immediate attention.
